A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized controlled trial of HER-2 positive breast cancer patients treated with
lapatinib and paclitaxel vs herceptin and paclitaxel with sequential and synchronous
anthracycline